You are here: News > Merger of US Pharmaceutical and Cell & Gene Therapy companies has potential to develop multiple promising new therapies

Merger of US Pharmaceutical and Cell & Gene Therapy companies has potential to develop multiple promising new therapies

Merger of US Pharmaceutical and Cell & Gene Therapy companies has potential to develop multiple promising new therapies

Merger of US Pharmaceutical and Cell & Gene Therapy companies has potential to develop multiple promising new therapies. The announcement several days ago of a merger of two US companies in the field of dermatology and cell and gene therapy is very positive news for the future development of therapies and products for EB.

Castle Creek Pharmaceutical Holdings have announced that they will acquire Fibrocell Science Inc. for a total consideration of approximately $63.3 million.

Castle Creek Pharmaceuticals is a biopharmaceutical company dedicated to developing and bringing new therapies to those living with Epidermolysis Bullosa. Fibrocell Science Inc. is a cell and gene therapy company focused on developing ‘game-changing cell and gene therapies for localized treatment of the underlying cause of debilitating diseases’, improving the lives of people with rare diseases of the skin and connective tissue.

Fibrocell’s portfolio includes an investigational, late-stage stage gene therapy product candidate for the treatment of RDEB which will augment Castle Creek Pharmaceuticals’ investigational, late-stage topical ointment under development for the treatment of EBS. Combining the two companies’ expertise and resources creates ‘the potential to develop multiple promising new therapies’ according to Greg Wujek, CEO of Castle Creek Pharmaceuticals.

Ben Merrett, CEO of DEBRA UK, is very optimistic about the benefits in terms of research and treatments for EB.

 ‘It is extremely encouraging that a single company will be leading two clinical trials into more than one type of EB.  We hope that sharing understanding of different approaches to finding treatments will speed up the time needed to get treatments to the EB community’

Make a difference

Make a difference

Please help us fund vital healthcare such as specialist EB nurses as well as research, care and life-changing support. 

Donate Today